Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mauna Kea Technologies's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 68.32.
Mauna Kea Technologies's Days Inventory for the
six
months ended in Dec. 2025 was 526.32.
Mauna Kea Technologies's Days Payable for the
six
months ended in Dec. 2025 was 538.79.
Therefore, Mauna Kea Technologies's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 55.85.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Mauna Kea Technologies Cash Conversion Cycle Related Terms
Mauna Kea Technologies Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Mauna Kea Technologies's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1MK vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Mauna Kea Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mauna Kea Technologies Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Mauna Kea Technologies's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Mauna Kea Technologies's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mauna Kea Technologies (FRA:1MK) has a Cash Conversion Cycle of 55.85 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Mauna Kea Technologies and its competitors.
Is Mauna Kea Technologies' Cash Conversion Cycle too high?
Mauna Kea Technologies' current Cash Conversion Cycle is 55.85. The Medical Devices & Instruments industry median Cash Conversion Cycle is 159.01. Mauna Kea Technologies' value of 55.85 is 64.9% below this industry median. Overall, Mauna Kea Technologies has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' Cash Conversion Cycle compare to ABT and SYK?
Mauna Kea Technologies' Cash Conversion Cycle of 55.85 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 159.01. Mauna Kea Technologies' value of 55.85 is 64.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 159.01, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mauna Kea Technologies's current Cash Conversion Cycle of 55.85 is 64.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Mauna Kea Technologies and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 159.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mauna Kea Technologies's current Cash Conversion Cycle is 55.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Mauna Kea Technologies (FRA:1MK) has a current Cash Conversion Cycle of 55.85. The stock's GF Value™ is €0.13, compared to a current price of €0.14 — trading 9.7% above its estimated fair value. The current Cash Conversion Cycle is 55.85 and 64.9% below the Medical Devices & Instruments industry median of 159.01. Mauna Kea Technologies' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Mauna Kea Technologies (FRA:1MK), the current Cash Conversion Cycle is 55.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mauna Kea Technologies (FRA:1MK) Overvalued in 2026?
Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued.
The current stock price of €0.14 is trading 9.7% above its estimated GF Value™ of €0.13.
Key valuation signals for FRA:1MK:
Cash Conversion Cycle: 55.85
GF Value™: €0.13 vs. price of €0.14 (9.7% above fair value)
Industry Position: 64.9% below the Medical Devices & Instruments median
No single metric tells the full story. See the FRA:1MK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
39GF Score
Get the complete analysis for FRA:1MK
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1MK has been successfully added to your 
